Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study

Background Rabies vaccines are lifesaving in human post animal exposure. However, the compliance to the complete course of vaccine is found to be only 60%. Hence, there is a need for safe and immunogenic, shorter course vaccine that can enhance the compliance and effectively prevent the disease. Obj...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Ravish H S, Akash Khobragade, Durga Satapathy, Monica Gupta, Surendra Kumar, Vinay Bhomia, Ramasubramanian V, Maharshi Desai, Ashok Dilipkumar Agrawal
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Taylor & Francis Group 2021-11-01
Seri Bilgileri:	Human Vaccines & Immunotherapeutics
Konular:	recombinant rabies g protein vaccine noninferiority safety immunogenicity simulated postexposure prophylaxis
Online Erişim:	http://dx.doi.org/10.1080/21645515.2021.1957413
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!